Mylan (MYL) is dealing with more negative reports on executive pay. The company, which has come under fire for the price of the life-saving EpiPen, has the second-highest executive compensation package in the industry, according to the Wall Street Journal. Over the past five years, Mylan has paid its top five managers a total of nearly $300 million. That figure is surprising because Mylan isn't that large of a company. The drug maker ranks 11 in the U.S. by revenue and 16 by market cap.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.